Long-term administration of PPAR-α agonists was associated with reduced lipotoxicity and inflammation, resulting in improved cardiac function in diabetic individuals and a notable decrease in cardiovascular risk factors commonly associated with diabetes [144]. This evidence concerns the gene PPARA and diabetes mellitus.